Drugs / FOR46
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03650491 | Apr 2019 → Jan 2022 | plasma cell myeloma | Fortis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03575819 | Feb 2019 → Nov 2023 | metastatic prostate carcinoma | Fortis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05011188 | Jan 2022 → Jul 2027 expected | prostate carcinoma | Rahul Aggarwal | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06842498 | Feb 2026 → Mar 2028 expected | castration-resistant prostate carcinoma | Kyntra Bio | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOR46 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05011188 ↗ |
| Known as | FG-3246 | “Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer.” PMID 40138611 ↗ Mar 2025 |
| Modality | Other / unclassified | “FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46” NCT03575819 ↗ |
| Route | Intravenous | “Eligible patients will receive FOR46 administered as an IV infusion every 21 days” NCT03575819 ↗ |
| Target | CD46 | “FOR46, a fully human antibody conjugated to monomethyl auristatin E, targets a tumor-selective epitope of CD46” PMID 40138611 ↗ Mar 2025 |